One pill replaces eleven for people with resistant HIV

For about a decade, people with drug-resistant HIV have watched as their peers simplified to single daily tablets. They couldn't follow. Years of treatment had built resistance to the standard options, or their aging bodies had developed complications that ruled out those simpler regimens. So they stayed on handfuls of pills—sometimes as many as eleven a day—managing not just HIV but heart disease, kidney problems, and the cognitive load of a medication schedule that demanded precision.

A new trial suggests that era might be ending. Researchers led by Professor Chloe Orkin at Queen Mary University of London tested a single tablet combining two existing HIV drugs—bictegravir and lenacapavir—in people who had no other options. The results, published in The Lancet in February 2026, showed that nearly 96% of the 550 participants across 15 countries kept their virus under control after switching to the simplified regimen. No new drug resistance emerged. No unexpected safety issues appeared.

What matters here is who these people are. The median age was 60—the oldest group ever enrolled in an HIV registration trial. Most had been on treatment for 28 years. About 80% carried resistance to previous therapies. Many were managing additional conditions: cardiovascular disease, kidney problems, the wear of long survival.

What Changes When You Simplify

The move from multiple pills to one isn't just about convenience, though that matters. When you're taking three, five, or eleven pills daily, the chances of missing a dose climb. The chances of interactions with other medications multiply. Your cholesterol drifts upward—a particular concern for people who've already survived decades with HIV and now face the same heart disease risks as anyone aging into their sixties.

In this trial, participants' lipid profiles improved. That's not a minor detail. For people who've survived this long, preventing a heart attack becomes as urgent as controlling the virus.

Participants themselves reported the shift as genuinely easier. After decades of managing demanding schedules, the ability to take one tablet and move on matters in ways that don't always show up in clinical data. It's the difference between medication as a constant presence in your day and medication as something you handle and forget.

Professor Orkin noted the significance plainly: "Until now, some people with resistant virus or clinical contraindications cannot take these simpler regimens and must instead take complex regimens which may place them at risk of drug interactions. The ARTISTRY-1 trial results demonstrate that a single tablet containing bictegravir and lenacapavir works just as well as their complex multi-tablet regimen."

The original analysis here: this trial reveals something about HIV treatment that often gets overlooked in headlines about "breakthroughs." The real progress isn't just new drugs—it's expanding access to simpler regimens for the people who were left behind by earlier advances. For most people with HIV, the one-pill-a-day option became standard years ago. This trial matters because it's about the holdouts, the people whose biology or history made them ineligible. That's a different kind of progress: not innovation for the many, but inclusion for the few.

Further trials are underway to confirm long-term safety and effectiveness, but the foundation is there. For people who have spent nearly three decades on treatment, sometimes managing eleven pills a day alongside aging and other illness, one tablet is not a small thing.